Study objective: The link between prescription opioid shopping and overdose events is poorly understood. We test the hypothesis that a history of prescription opioid shopping is associated with increased risk of overdose events.
INTRODUCTION Background
Drug overdoses have exceeded motor vehicle crashes as the leading cause of accidental mortality in the United States, and this epidemic has been fueled by prescription opioid abuse. 1 From 1995 to 2015, more than 183,000 people have died in the United States from overdoses related to prescription opioids. 2 Although North America has been the epicenter of this public health crisis, 3 increasing rates of opioid prescribing have been observed in multiple countries. [4] [5] [6] [7] [8] There has been specific interest in "shoppers" who obtain prescription opioids from multiple prescribers or pharmacies. [9] [10] [11] [12] [13] [14] Shopping may contribute to overdose events either through risky prescription opioid use (eg, overlapping prescriptions) or by diversion of legally prescribed opioids to other individuals for illicit use. 15 Shopping may also be a marker for poorly coordinated pain management. 16 Opioid shopping may be particularly prevalent in emergency department (ED) settings, where care is delivered episodically. 13, 17, 18 Previous studies suggest that physician and pharmacy shopping is associated with increased risk of death. Two of these studies lacked data on patient comorbidities, so results may have been confounded by unmeasured case mix. 9, 10 A third report relied on pharmacy claims data, 16 which may be an inaccurate measure of opioid dispensing, particularly among shoppers who often pay in cash. 11 Understanding the relationship between opioid shopping and overdose events is particularly important for Medicaid beneficiaries (typically lower-income individuals in the United States who qualify for state-based health benefits), who have a 6-fold higher risk of fatal prescription opioid overdose compared with non-Medicaid populations.
Editor's Capsule Summary

What is already known on this topic
The relationship between the use of multiple prescribers or pharmacies for controlled substances and substance abuse has not been established.
What question this study addresses
A retrospective cohort design was used to identify opioid shoppers, patients who used multiple providers and pharmacies for opioid prescriptions, among Washington Medicaid beneficiaries with a pain-related office or emergency department visit in 2014. Two thousand five hundred seventy-one opioid shoppers were matched to 2,571 nonshoppers according to demographic and case-mix characteristics.
What this study adds to our knowledge The nonfatal overdose rate was similar between opioid shoppers and nonshoppers.
How this is relevant to clinical practice
Opioid shopping was not directly related to nonfatal overdoses in a state Medicaid population.
Importance
Payers and case management programs are increasing efforts to profile patients with prescription opioid shopping behavior. 20, 21 Virtually all state Medicaid programs and many commercial payers have implemented "lock-in" programs, which restrict opioid shoppers to a single prescriber and pharmacy. 22 However, the expected mechanism of action is unclear, and improved knowledge may influence program design. If shopping is associated with independent overdose risk to the recipient of the prescriptions, then lock-in programs would be expected to directly reduce overdose events in patients with shopping behavior by restricting prescribers and pharmacies.
Alternatively, if shopping is not associated with overdose risk, then lock-in programs may reduce overdoses through reductions in opioid supply (both to targeted beneficiaries and to others who receive diverted opioids), rather than through restriction of prescribers and pharmacies. In this scenario, additional resources such as pain treatment specialists may be needed to address independent overdose risk factors (eg, total quantity of prescription opioids, overlapping opioid and benzodiazepine prescriptions) that are associated with opioid shopping.
Goals of This Investigation
Using data from a large cohort of Medicaid beneficiaries, we analyzed linked claims and prescription drug monitoring program data to test the following hypothesis: a history of prescription opioid shopping is associated with increased risk of nonfatal overdose events.
MATERIALS AND METHODS Study Design
We performed a retrospective cohort study of Washington State Medicaid beneficiaries. Washington State provided medical claims and prescription drug monitoring program data linked at the beneficiary level for calendar years 2013 to 2015. Data from 2014 were used as the intake period during which patients could enter the cohort. Data from 2013 and 2015 were also included to allow assessment of history of patient comorbidities and outcomes, respectively. Claims data used International Classification of Diseases, Ninth Revision (ICD-9) diagnostic codes (ie, the study time frame preceded nationwide adoption of ICD-10 codes in October 2015). The prescription drug monitoring program is an electronic record of all controlled substances dispensed by Washington State pharmacies. Unlike Medicaid pharmacy claims data, which may miss medications paid by a coinsurer or in cash, the prescription drug monitoring program captures all dispensed opioids regardless of payer.
The Washington Department of Heath links Medicaid and prescription drug monitoring program data at the beneficiary level for quality improvement purposes. An external data vendor developed a methodology that uses a combination of deterministic linkage (eg, on name, date of birth, and address) and a clustering algorithm to combine potentially related prescription drug monitoring program records (eg, slight variations on linking variables such as "John Doe" and "Jon Doe"). Department of Health staff performed validation on a criterion-standard manually reviewed set of 997 linked records pairs and 1,002 nonlinked pairs. The matching algorithm has a sensitivity of 67% and specificity of greater than 99%.
The institutional review boards of Washington State and of Oregon Health & Science University approved this study before data collection.
Selection of Participants
Washington State Medicaid beneficiaries were eligible to enter the cohort between January 1, 2014, and December 31, 2014. We focused on ambulatory care encounters for which opioid prescribing might be considered. Patients entered the study cohort on the date that the following criteria were met: (1) 23, 24 (see Table E1 , available online at http://www.annemergmed.com) that represented a potential opportunity to prescribe an opioid medication; (2) the encounter did not result in hospitalization or observation care; (3) the patient had a history of prescription for opioid medication in the 6 months before the encounter; and (4) the patient had continuous Medicaid enrollment for the 6 months before and after cohort entry (to allow standardized assessment of preexisting comorbidities and outcomes subsequent to cohort entry).
We excluded members with a 1-year history of cancer. 25 We excluded beneficiaries who were dually eligible for Medicare and Medicaid during the study period because linked Medicare use and pharmacy data were unavailable. Children younger than 15 years were excluded. Finally, we excluded patients who received hospice or nursing home care at any time during the study period because opioid analgesics are a widely accepted treatment for hospice patients, 27 and institutional providers are likely responsible for medication management in nursing facilities.
Outcome Measures
The primary outcome was the occurrence of a nonfatal overdose event within 6 months after cohort entry. We defined nonfatal overdose with an ICD-9 code for opioid poisoning or opioid-related adverse events in addition to a diagnosis on the same date that may have been related to overdose (see Table E2 , available online at http://www. annemergmed.com). 26 The independent variable of opioid shopping was defined as opioid prescriptions by different prescribers with greater than or equal to 1-day overlap and filled at 3 or more pharmacies in the 6 months before cohort entry. 11 We believe that our definition, based on the work of Cepeda et al, 11 is highly specific to aberrant use patterns because it requires multiple prescribers, multiple pharmacies, and overlapping prescriptions. We acknowledge that other studies have used a wide range of thresholds and "look-back" time frames to define opioid shopping. 10, 12, 16, [27] [28] [29] [30] We performed sensitivity analyses to assess the effect of various definitions of opioid shopping (see "Primary Data Analysis" below).
We included an expansive set of patient-level case-mix measures, evaluated during each calendar quarter, that may be associated with prescription opioid use and overdose events. Demographics included age, sex, race, Hispanic ethnicity, federal poverty level, and disability status. A 1-year history of 17 physical health condition categories was evaluated with the Chronic Illness and Disability Payment System, which has been validated for use in Medicaid populations. 31 Specific mental health and substance abuse diagnoses were identified through medical claims with the previously described Ettner classification system. 32 To control for potential temporal trends, we included dummy variables indicating the calendar quarter of cohort entry.
We created 2 measures of high-risk prescription opioid use in the 6 months before cohort entry that may be predictors of overdose events and potentially confound the relationship between opioid shopping and outcomes. 25, 28, 33, 34 We calculated total dispensed morphine milligram equivalents, using the following conversion factors [35] [36] [37] : codeine 0.15, fentanyl citrate 0.13, fentanyl patch 7.2, hydrocodone 1, hydromorphone 4, levorphanol 11, meperidine 0.1, methadone 3, morphine 1, oxycodone 1.5, oxymorphone 3, and tapentadol 0.4. We considered only oral or transdermal formulations. We also measured whether there was any previous instance of overlapping opioid and benzodiazepine prescriptions for more than 1 week.
Primary Data Analysis
We used a propensity score to match shoppers to nonshoppers; we then calculated the risk difference between the 2 matched groups (ie, we did not generate a propensity score-adjusted regression model).
We used propensity score matching to control for baseline imbalances in measured covariates. 38 A logistic regression model to predict opioid shopping included all covariates described in the previous section.
We used nearest neighbor matching with replacement to identify one nonshopper (control) for each shopper (treated). 39 To assess the validity of propensity score matching, we report standardized differences in baseline characteristics before and after matching. A standardized difference with an absolute value less than 0.1 suggests negligible imbalance in the mean or prevalence of a covariate between the treatment and control groups. 40 We used methods for paired data to estimate absolute risk differences and 95% confidence intervals for outcomes. 41 Observations that were missing age (0.14%) and sex (0.53%) were omitted from the analysis. A small number of observations that were missing information for federal poverty level (0.0007%) were omitted from the analysis. Observations with missing race and ethnicity were categorized as "unknown" and included in the analysis. After cohort selection, we had no missing morphine milligram equivalent data. Comorbidities were coded as presence or absence of diagnosis codes, and disability status and expansion were also coded as presence or absence and therefore had no missing values.
We performed multiple sensitivity analyses. We considered the possibility that total morphine milligram equivalents and overlapping opioid and benzodiazepines prescriptions were mediating (ie, colinear) rather than confounding factors; in sensitivity analyses, we excluded these variables from the propensity score model. We assessed whether our findings were sensitive to the lookback period (6 months versus 90 days) to define shopping. Finally, we repeated our analyses with alternative definitions of opioid shopping (ie, 3, 4, and 5 prescribers or pharmacies in the previous 6 months).
All data management and statistical analyses were performed in R (version 3.3.242; The R Foundation, Vienna, Austria) and Stata MP (version 14.0; StataCorp, College Station, TX). 42 
RESULTS
Of 2,238,568 unique Washington State Medicaid members in 2014, there were 66,328 patients who met study inclusion criteria (Figure) . Six-month nonfatal overdose occurred in 290 patients (0.4%) in the overall cohort. We identified 2,571 opioid shoppers (3.9%) who had opioid prescriptions by different prescribers with greater than or equal to 1-day overlap and filled at 3 or more pharmacies in the 6 months before cohort entry.
Baseline characteristics differed on multiple attributes between shoppers and nonshoppers (Table 1) . Shoppers were more likely to have risk factors for overdose events, including higher amounts of prescribed morphine milligram equivalents, overlapping opioid and benzodiazepine prescriptions, and preexisting substance abuse diagnosis. Shoppers were also more likely to have a pain-related ambulatory care visit early in the study year, and to have multiple preexisting physical and mental health diagnoses. A 1:1 propensity score matching identified a comparison cohort with minimal differences (absolute standardized difference <0.1) between opioid shoppers and matched nonshoppers for all covariates ( Table 1, Table E3 [available online at http://www.annemergmed.com], and Figure E1 [available online at http://www.annemergmed. com]).
In unadjusted analyses (Table 2) , shoppers had a higher rate of 6-month nonfatal overdose events compared with nonshoppers (rate difference of 4.4 events per 1,000; 95% confidence interval 0.8 to 7.9). After propensity score matching (Table 2) , we found no difference in the primary outcome (rate difference of 0.4 events per 1,000; 95% confidence interval -4.7 to 5.5) between opioid shoppers and nonshoppers.
Our findings were robust to multiple sensitivity analyses, including exclusion of previous morphine milligram equivalents and opioid or benzodiazepines as potential mediating factors, a shorter (90-day) look-back period, and alternative definitions of shopping (including 3, 4, and 5 prescribers or pharmacies in the previous 6 months) ( Table 3) .
LIMITATIONS
First, we acknowledge that there are many potential definitions of shopping, and our definition may be triggered by appropriate medical use (eg, multiple providers at a safety net clinic, housing instability resulting in multiple dispensers). However, our findings are robust to alternative definitions and look-back time frames. Second, we considered all-cause mortality in a composite outcome with nonfatal overdose. However, we identified only three 6-month deaths in the analytic cohort. Our findings did not change when these 3 fatal events were considered in a composite outcome including nonfatal overdose. Third, we studied Washington State Medicaid beneficiaries because of increased opioid overdose risk in this population, 19 and our believe that the modest sensitivity of prescription drug monitoring program linkage may reduce the power but not validity of our findings. False-negative matches (opioid users without linked prescription drug monitoring program data) are already accounted for in our excluded patients (ie, no evidence of previous opioid use). The high specificity of matching increases confidence that we correctly identified shoppers. Sixth, we analyzed all available data but did not perform a formal sample size calculation. It is possible that we had insufficient event rates to detect small but clinically importance outcome differences.
DISCUSSION
In this large cohort of Medicaid beneficiaries, a history of prescription opioid shopping behavior was not associated with increased risk of nonfatal overdose events after adjusting for previous opioid use, patient demographics, substance abuse disorders, and other diagnoses. These findings were robust to multiple sensitivity analyses. Our study builds on previous research on shoppers by including extensive comorbidity data from medical claims; using comprehensive prescription drug monitoring program dispense data; capturing nonfatal overdose events, which are much more common than fatal overdoses; and using propensity score methods to mitigate confounding by measurable factors. Our findings suggest that interventions to reduce overdose risk among recipients of prescription opioids should focus on factors other than shopping behavior.
Our results differ from those of previous reports, which suggested an increased risk of mortality or overdose events associated with shopping behavior. In our cohort, shoppers had increased physical and mental health comorbidities, as well as riskier patterns of opioid use (eg, total prescribed morphine milligram equivalents, overlapping prescriptions with benzodiazepines). In unadjusted analyses, shoppers had significantly higher rates of nonfatal overdoses than did nonshoppers. However, these differences disappeared after balancing of baseline characteristics, suggesting that the link between shopping and adverse events is explained by other associated, high-risk factors.
Two previous case-control studies used prescription drug monitoring program data to identify risk factors for fatal overdoses. Peirce et al 9 studied 698 decedents and 1,049,205 living controls who were prescribed a controlled Risk factors for death include 4 or more prescribers per year, 4 or more pharmacies, and greater than 100 daily morphine milligram equivalents per year. However, these analyses were restricted to dispensing and demographic data available through the state prescription drug monitoring programs, and neither study included data on patient comorbidities, which may confound the relationship between opioid shopping and outcomes. A recent study by Yang et al 16 of 90,010 Medicaid beneficiaries receiving long-term opioid therapy explored the link between pharmacy shopping, overlapping prescriptions, and overdose events. In multivariate analyses, a history of pharmacy shopping (4 pharmacies in 90 days) was associated with a hazard ratio of 1.8 for opioid overdose. Overlapping prescriptions were associated with a hazard ratio of 3.0. Our study used a definition of shopping that incorporated both multiple pharmacies and overlapping prescriptions, and our findings differ from the work by Yang et al. 16 There are many methodological similarities between this report and our study (including the use of a Medicaid beneficiary population, the same definition for nonfatal overdose events, 26 and control of comorbidities). However, Yang et al 16 used Medicaid pharmacy claims data to identify shopping and control for baseline morphine milligram equivalents, whereas our study used prescription drug monitoring program data that identified the dispensing of opioids regardless of payment source, including cash. Tracking the purchase of opioids by cash payments may be critical because as many as 45% of shoppers may pay with cash for prescription opioids. 11 Use of pharmacy claims could introduce differential measurement bias among shoppers versus nonshoppers, which may explain the discrepancy between our study and the findings by Yang et al. 16 Finally, the study by Yang et al 16 included long-term opioid users, and this population may be different from ours because of our inclusion criteria of any opioid medications in the 6 months before enrollment.
Although we did not find a causal link between shopping and outcomes, our study required extensive data sets and complex analytic tools that are unlikely to be available to front-line prescribers. We suggest an approach to translating our findings to routine clinical practice. Almost all states operate a prescription drug monitoring program, 43 which allows prescribers to screen for opioid shopping behavior without the need for previous knowledge of patient characteristics or medication use. Prescribers should strongly consider nonopioid pain management and referral to case management programs for all patients with shopping behavior. Evidence of opioid shopping behavior should alert prescribers to identify and manage associated independent predictors of overdose, including total quantity of prescribed opioids and overlapping prescriptions for opioids and benzodiazepines. 25, 28, 33, 34 Although physician use of prescription drug monitoring programs has historically been low, 44 initiatives to "push" prescription drug monitoring program data to electronic medical records at patient registration 45 and embed clinical decision support may overcome logistic barriers to prescription drug monitoring program use. 46 11 with a 6-month look-back for history of opioid use. The morphine milligram equivalents and opioid/benzo overlap covariates were not included in the propensity score models. † The shopper is defined according to the study by Cepeda et al, 11 with a 90-day look-back for history of opioid use. The morphine milligram equivalents and no opioid/benzo overlap covariates are included in the propensity score model. ‡ The shopper is defined as an individual with at least 3 pharmacies or 3 prescribers in the past 6 months from cohort entry date. § The shopper is defined as an individual with at least 4 pharmacies or 4 prescribers in the past 6 months from cohort entry date.
k Our findings provide additional insights into policy approaches to curtailing opioid shopping. Shoppers have been targeted by policies attempting to limit the supply of prescription opioids, reduce health care costs, and prevent overdoses. Virtually all state Medicaid programs and many commercial payers have implemented lock-in programs, which restrict opioid shoppers to a single prescriber and pharmacy. 22 Prescription drug monitoring programs allow prescribers and pharmacies to identify opioid shopping behavior. Despite substantial heterogeneity in lock-in and prescription drug monitoring program programs, both are associated with reduced shopping behavior, health care encounters, and costs. 22, 43 The effect of these policies on overdose events is less clear, although emerging evidence suggests an association between prescription drug monitoring programs and reduction in overdose events and mortality. 43 Lock-in programs may prevent overdoses through 2 potential and nonexclusive mechanisms: reduced risk to targeted patients, and reduced diversion to other individuals. Our findings provide some evidence that restricting patients to a single prescriber or pharmacy may not independently reduce risk, although lock-in programs may have beneficial effects in modifying other risk factors for overdose (eg, reducing total morphine milligram equivalents). Although we did not specifically study diversion (the second potential mechanism), others have assessed the link between diversion and overdose events. Qualitative research with prescription-drug abusers identified physician shoppers as a major source of diverted opioids. 15 In a case series of 295 fatal, unintentional prescription overdose events, physician shopping (>5 prescribers in the year before death) was found in 21%. 47 Diversion (ie, death from a prescription drug without evidence of a prescription) was found in 63% of events, suggesting that a majority of fatal overdoses may be related to diverted medications rather than to opioids prescribed by physicians. These studies suggest that lock-in programs may reduce overdose in part by limiting diversion, although the direct effect may be difficult to measure.
In summary, prescription opioid shopping is not independently associated with increased risk of overdose events. Screening criteria for interventions to reduce overdose risk should focus on high-risk characteristics associated with shopping. Figure E1 . Propensity score distribution before and after matching. Only one line is visible in the matched distribution because of complete overlap of treated (shoppers) and control (nonshoppers) groups. Table E2 . ICD-9 codes used to identify nonfatal overdose. Reference group is January to March 2014.
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